Hikma Pharmaceuticals: Hypertension trials

The registry lists 10 Hypertension studies with Hikma Pharmaceuticals as lead sponsor. 0 are open to participants now and 0 have results posted.

No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted ConditionsCompletedNCT01712139Not applicable
• Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed ConditionsCompletedNCT01712126Not applicable
• Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted ConditionsCompletedNCT01712113Not applicable
• Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed ConditionsCompletedNCT01712100Not applicable
• Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fed ConditionsCompletedNCT01216878Not applicable
• Bioequivalency Study of Losartan Potassium 100 mg Tablet Under Fasted ConditionsCompletedNCT01216852Not applicable
• Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg/25 mg Tablet Under Fasted ConditionsCompletedNCT01102478Not applicable
• Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed ConditionsCompletedNCT01102465Not applicable
• Bioequivalency Study of Ramipril 10 mg Capsules Under Fed ConditionsCompletedNCT00702260Not applicable
• Bioequivalency Study of Ramipril 10 mg Capsules Under Fasting ConditionsCompletedNCT00702091Not applicable